Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · IEX Real-Time Price · USD
1.180
+0.070 (6.31%)
Jul 23, 2024, 4:00 PM EDT - Market closed

Virax Biolabs Group Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.
Year Ending
TTM Mar 31, 2023Mar 31, 2022Mar 31, 2021Mar 31, 2020
Net Income
-6.92-5.46-1.71-0.65-0.71
Share-Based Compensation
1.591.750.2900
Other Operating Activities
-0.01-0.480.610.06-0.03
Operating Cash Flow
-5.34-4.18-0.81-0.59-0.74
Capital Expenditures
-0.71-0.18000
Investing Cash Flow
-0.71-0.18000
Share Issuance / Repurchase
7.113.650.520.40
Debt Issued / Paid
-0.420.030.290.180.7
Other Financing Activities
0.09----
Financing Cash Flow
6.7713.690.810.590.7
Net Cash Flow
0.549.330-0-0.04
Free Cash Flow
-6.05-4.36-0.81-0.59-0.74
Free Cash Flow Margin
-7628.04%-50907.25%--476.65%-745.54%
Free Cash Flow Per Share
-3.41-4.10-0.85-2.45-7.13
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).